A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

NCT05877222 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Daridorexant 10 mg
DRUG: Daridorexant 25 mg

Sponsor

Idorsia Pharmaceuticals Ltd.